|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
California Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing CaliforniaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Ciclofilin Pharmaceuticals Inc.
| | | Year Established: | 2014 | Ticker: | CTRV | Exchange: | NASDAQ | Main Contact: | Michael Kamdar, MBA, President | | Other Contacts: | Dan Trepanier, PhD, Director of Product Development Daren Ure, PhD, Director of R&D Robert Foster, CEO
| | Company Description | Ciclofilin Pharmaceuticals, formerly Isotechnika, is developing a clinically effective treatment for hepatitis C virus (HCV)/HIV-1 co-infection, with specific antiviral activity directed against both viruses.
On June 13, 2016, ContraVir Pharmaceuticals announced it had completed its merger with Ciclofilin Pharmaceuticals, acquiring all of its outstanding equity interests. | |
|
|
|
|
|